Go Pro
NASDAQ:ALEC

Alector Q1 2026 Earnings Report

Alector logo
$2.35 -0.04 (-1.67%)
As of 11:09 AM Eastern

Alector EPS Results

Actual EPS
-$0.21
Consensus EPS
-$0.29
Beat/Miss
Beat by +$0.08
One Year Ago EPS
N/A

Alector Revenue Results

Actual Revenue
$1.05 million
Expected Revenue
$9.67 million
Beat/Miss
Missed by -$8.63 million
YoY Revenue Growth
N/A

Alector Announcement Details

Quarter
Q1 2026
Time
Before Market Opens
Conference Call Date
Thursday, May 7, 2026
Conference Call Time
7:00AM ET

Upcoming Earnings

Alector's Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Alector Earnings Headlines

Don’t Buy Bitcoin Until You Read This
Bitcoin just erased three months of losses, surging 28% in eight days to top $80,000 for the first time in 15 weeks. TradeSmith has invested $17 million in AI research since 2022, building tools that helped forecast the 2020 crash and back-tested signals for 2000 and 2008. CEO Keith Kaplan says the data points to a different move before August 31.tc pixel
Alector: Q2 Earnings Snapshot
See More Alector Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Alector? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alector and other key companies, straight to your email.

About Alector

Alector (NASDAQ:ALEC) is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2013, the company is focused on discovering and developing immuno-neurology therapies that target the innate immune system to treat a range of neurodegenerative disorders. Alector’s approach aims to harness the body’s natural defense mechanisms to clear pathological proteins and restore neuronal function in conditions such as Alzheimer’s disease and frontotemporal dementia.

The company’s pipeline includes multiple product candidates in both preclinical and clinical stages, with lead programs AL001 and AL002 advancing in frontotemporal dementia and Alzheimer’s disease studies. Alector designs its molecules to engage key immune receptors in the brain, seeking to slow or halt disease progression rather than simply address symptoms. Research and development activities are supported by state-of-the-art laboratories in North America and collaborations with academic and industry partners in Europe.

Since completing its initial public offering in 2019, Alector has expanded its clinical footprint through strategic alliances and investigator-initiated trials. The company maintains global development programs aimed at bringing the first approved immuno-neurology therapies to patients worldwide.

Alector is led by co-founder and Chief Executive Officer Dr. Arnon Rosenthal, a neuroscientist with over two decades of experience in immunology and drug discovery. The management team brings extensive backgrounds in clinical development, regulatory affairs, and commercialization, supporting Alector’s mission to transform the treatment landscape for neurodegenerative diseases.

View Alector Profile